Featured Education

On Demand Activities

More results...

Therapeutics Areas
Learner Specialties
Expires After
  • On-Demand
Prognostic Factors
  • Credit: 0.25hr(s)
  • CME
  • September 16, 2024 — 
  • September 15, 2025
  • Therapeutic Areas: Oncology
  • Specialties: Breast Cancer
  • Location: Internet Activity Enduring
Educating patients about treatment and survival of metastatic breast cancer is strongly linked to the cancer’s prognostic factors. What you will learn from this module: Learn the importance of educating patients about their specific metastatic breast cancer, focusing on its prognostic factors. Be able to teach a patient how their breast cancer treatments and prognosis may be different from other metastatic breast cancer patients they meet. Determine the optimal way to provide this education so it is understood by your patient.
Access Course
  • On-Demand
Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disorders: Addressing Unmet Needs with Emerging Therapies
  • Credit: 1.00hr(s)
  • AAPA, CME, ILNA, IPCE, MOC
  • September 25, 2024 — 
  • September 24, 2025
  • Specialties: Epstein-Barr virus (EBV), Post-Transplant Lymphoproliferative Disorders (PTLD)
  • Location: Internet Activity Enduring
In this Hematology Dialogues, Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disorders: Addressing Unmet Needs with Emerging Therapies, participants will learn about the epidemiology and burden of Epstein-Barr Virus-positive (EBV+) and post-transplant lymphoproliferative disorders (PTLD), differentiate between current and emerging prognostic scoring systems for EBV+ and PTLD to inform treatment decisions, and evaluate the latest clinical evidence of emerging treatment options for EBV+ and PTLD. Experts will discuss hot topics in the field of EBV+ and PTLD as well as respond to patient cases and provide commentary relating to how they have responded to complex treatment decisions, thereby ensuring optimal clinical outcomes. This independent satellite symposium is derived from the Society of Hematologic Oncology 2024 Annual Meeting, originally held on September 5, 2024.
Access Course
  • On-Demand
Time Well Spent: Treating Obesity and Diabetes
  • Credit: 1.0hr(s)
  • AAPA, CME, NCPD
  • November 10, 2023 — 
  • November 9, 2024
  • Therapeutic Areas: Family Medicine / Primary Care
  • Specialties: Diabetes, Obesity, Primary Care
  • Location: Internet Activity Enduring
Community Collective: Time Well Spent – Navigating the Challenges of Treating Obesity and Diabetes is an educational curriculum designed for rural primary care clinicians to enhance outcomes for individuals with obesity through improved diagnosis and use of therapy options to treat type 2 diabetes (T2D).
Access Course
  • On-Demand
Recognizing the Profound Impact on Quality of Life: Emerging Therapy Options for Patients with Myelofibrosis
  • Credit: 1.0hr(s)
  • ILNA, NCPD
  • July 15, 2024 — 
  • June 14, 2025
  • Therapeutic Areas: Chronic Lympoblastic Leukemia (CLL), Hematologic Oncology, Hematology, Oncology
  • Specialties: Myelofibrosis
  • Location: Internet Activity Enduring
In this combined enduring and live ONS chapter meeting activity, Recognizing the Profound Impact on Quality of Life: Emerging Therapy Options for Patients with Myelofibrosis, learn from expert faculty to effectively identify how JAK inhibitors and emerging treatments for myelofibrosis (MF) optimize clinical outcomes by improving overall patient quality of life (QOL). Learners will first participate in an enduring online program on the following topics: patient risk and drug mechanisms of action for effective treatment and management, gaps in MF care that influence patient QOL, disease- and treatment-related adverse events, trust with patients to improve outcomes and QOL, shared decision-making and the unique role of multidisciplinary teams. After completion of the enduring program, learners will have the opportunity to network with expert faculty at select live ONS chapter meetings at which time they will discuss various case studies regarding treatment selection and patient QOL. Learners will also participate in discussion questions and have time for one-on-one interaction with faculty and others nursing professionals.
Access Course
  • On-Demand
Advances in Non-Hodgkin Lymphoma Care: Navigating New and Emerging Treatments
  • Credit: 0.25hr(s)
  • AAPA, ABIM, CME, CPE, MOC, NCPD, Royal College MOC 
  • May 15, 2024 — 
  • May 14, 2025
  • Therapeutic Areas: Pan Tumor, Pathology, Pharmacy
  • Specialties: Pathology, Pharmacy
  • Location: Internet Activity Enduring
In this first episode, “Making the Right Selection: Expert Guidance on Treatment Sequencing of T-cell Mediated Therapies,” from the 4-part series Med Table Talk, “The Power of the Community: Translating Innovations into Care in NHL and HL,” learn from expert faculty about unmet needs for patients with NHL based on an understanding of disease- and patient-related characteristics. Additionally, learn how to best assess eligible patients among new and emerging CAR T-cell and bispecific antibody therapies. Expert faculty will also discuss both the mechanisms of action of CAR T-cell and bispecific antibodies. This episode will conclude with a patient case study, which will consist of a dialogue between faculty.
Access Course
  • On-Demand
Recognizing the Profound Impact on Quality of Life: Emerging Therapy Options for Patients with Myelofibrosis
  • Credit: 1.00hr(s)
  • ILNA, NCPD
  • July 15, 2024 — 
  • July 14, 2025
  • Specialties: Hematology, Myelofibrosis, Oncology
  • Location: Internet Activity Enduring
In on-demand activity, Recognizing the Profound Impact on Quality of Life: Emerging Therapy Options for Patients with Myelofibrosis, learn from expert faculty, Jeanne Palmer, MD and Jennifer Andres, APRN, FNP, MSN as they discuss Profound Impact on Quality of Life: Emerging Therapy Options for Patients with Myelofibrosis, to effectively identify how JAK inhibitors and emerging treatments for myelofibrosis (MF) can optimize clinical outcomes and patient quality of life (QOL). Gain expert insights from enduring online program focuses on patient risk and drug mechanisms of action for effective treatment and management, gaps in MF care that influence patient QOL, disease- and treatment-related adverse events, trust with patients to improve outcomes and QOL, as well as shared decision-making and the unique role of multidisciplinary teams.
Access Course
View All MLI Activities
Facebook Twitter Linkedin Instagram
Subscribe to Mailing List
Scroll to Top